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Abstract 
Background: Normative data are necessary for validation of new outcome measures. Recently, the 95th centile 
of stride speed was qualified by the European Medicines Agency as a valid secondary outcome for clinical trials in 
subjects with Duchenne muscular dystrophy. This study aims to obtain normative data on spontaneous stride velocity 
and length in a non-controlled environment and their evolution after 12 months.
Method: Ninety-one healthy volunteers (50 females, 41 males), with a mean age of 16 years and 2 months, were 
recruited and assessed at baseline and 12 months later. The 4-stair climb, 6-min walk test, 10-m walk test and rise from 
floor assessments were performed. Stride length, stride velocity, and the distance walked per hour were studied in an 
everyday setting for one month after each evaluation.
Results: Of the 91 subjects assessed, 82 provided more than 50 h of recordings at baseline; and 73 subjects provided 
the same at the end of the year. We observed significant positive correlations of the stride length with age and height 
of participants, and a significant increase of the median stride length in children after the period. In this group, the 
95th centile stride velocity was not correlated with age and was stable after one year. All measures but the 10MWT 
were stable in adults after a one-year period.
Conclusion: This study provides with data on the influence of age, height, and gender on stride velocity and length 
as well as accounting for natural changes after one year in controls.
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Background
Duchenne muscular dystrophy (DMD) is a severe, rap-
idly progressive neuromuscular disorder characterized 
by muscle weakening. It has an estimated incidence of 1 
in 5000 males [1]. DMD is caused by out-of-frame muta-
tions in the dystrophin gene, which leads to an absence or 
deficiency of the protein dystrophin and the degeneration 
of muscles fibres [2]. Therefore, loss of ambulation occurs 
generally around the age of 12.
The 6-min walk distance test (6MWT) has been used 
as a primary outcome in most published pivotal phase 2 
and 3 trials in ambulant patients with DMD [3–6]. Other 
outcomes used include the 4-stair climb (4SC) and func-
tional scales such as the North Star Ambulatory Assess-
ments (NSAA) in which participants are rated on their 
ability to perform standardized motor function tasks [3, 
5–10]. In DMD, the low Standardized Response Mean 
of these different outcome measures, which illustrates 
the power of these measures to demonstrate a change 
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over a certain period of time, meant that pivotal tri-
als required over 100 patients per group and trial dura-
tions of 18  months and 2  years (NCT02851797 and 
NCT02500381, respectively). To accelerate clinical devel-
opment and investigate in parallel several approaches 
without being limited by the number of patients availa-
ble, it is crucial to validate more powerful outcome meas-
ures. This is the case for DMD and for numerous other 
rare diseases, within or outside the neuromuscular field.
The last decade has seen an increase in the availabil-
ity of wearable technology for continuous monitoring of 
health and wellbeing [11]; for example, wearable devices 
that can be used to assess ambulation range from crude 
step counters to sophisticated multisensory systems [12]. 
Unlike consumer devices, medical devices must dem-
onstrate validated measurement accuracy, sensitivity, 
and specificity [13]. Wearable devices have the potential 
to provide a complete view of a patient’s condition over 
a long time period by band-pass filtering day-to-day 
variation. Therefore, wearable devices provide a comple-
mentary approach with a major advantage over hospital-
based assessments, which only provide ‘snapshots’ of a 
patient’s condition that can be affected by fatigue, illness, 
or lack of motivation.
In this context, Sysnav, a medium size private company, 
along with academic partners specifically developed 
a CE-marked class 1 wearable medical device, called 
Actimyo®, that records passively, in a precise and sensi-
tive way, upper and lower limb movements in everyday 
life [14, 15]. From the capture of any single movement, 
several outcomes may be extracted. In ambulant patients, 
the identification and quantification of every individual 
stride allows for the calculation of the distribution of 
stride length and stride speed as well as for the analyses 
of different centiles such as the 95th centile stride veloc-
ity (SV95C). These variables are measured in a home-
based environment over a 180-h period and are reliable 
and highly sensitive to changes in ambulant patients with 
DMD [16].
Recently, the EMA qualified SV95C as a valid second-
ary endpoint in clinical trials on ambulant patients with 
DMD [17]. Additional data are needed to qualify the 
measure as a primary endpoint [16]. Wearable technol-
ogy is or has been used in clinical trials of therapies for 
spinal muscular atrophy [18, 19], facioscapulohumeral 
muscular dystrophy (NCT02579239, NCT04004000), 
limb girdle muscular dystrophy type 2E (NCT02579239), 
centronuclear myopathy (NCT02057705), and Angelman 
syndrome (NCT04259281).
To properly interpret the longitudinal evolution of 
the SV95C over time in patient populations, it is neces-
sary to understand the longitudinal evolution in subjects 
without muscle conditions within the same age range, in 
particular between 5 and 18  years old, which is the age 
range mostly targeted in clinical trials of ambulant DMD 
patients and during which growth or maturational fac-
tors may significantly interfere with measures [20, 21]. 
Therefore, we conducted a longitudinal study in ambu-
lant healthy subjects between 5 and 85  years of age to 
evaluate the changes in SV95C, as measured with the 
Actimyo® device, after a 12-months follow-up.
Method
Study design
We designed a monocentric academic study that was 
conducted in the Reference Centre for Neuromuscular 
Disease in Liège, Belgium between July 2017 and Sep-
tember 2019 with grant funding from Action Duchenne. 
The protocol was approved by the local ethics committee 
in Liège (N/Ref:1646). Before inclusion, all participants 
or parents or legal guardians provided written informed 
consent for participation and publication.
Participants
The initial protocols planned to include a maximum of 
130 healthy subjects to gather a distribution of about 
5–10 subjects par age year in children and a group of 
30 adults. However, due to difficulties in recruiting con-
trols—mainly in the adult age group—91 healthy subjects 
above the age of 5  years were assessed at baseline and 
84 were assessed after 12 months. The exclusion criteria 
were occurrence of surgery or recent trauma in the upper 
or lower limbs within six months prior to the first visit; 
participating in sport at a high (national) level; pregnant 
or breastfeeding women; occurrence of muscular, neu-
rological, infectious, acute, or chronic inflammatory dis-
ease within three weeks of inclusion date; and occurrence 
of orthopaedic, neuromuscular, or neurological disease 
with an impact on the quality of the walk.
Demographic data as well as medical and surgical his-
tories were obtained during the baseline visit. A full 
physical examination, including weight, height, and 
vital signs, was performed at the first visit and at the 
12-month visit. The subjects performed the 6MWT while 
wearing the sensors at baseline and at 12 months. They 
also performed the 4SC, rise from floor (RFF), and 10-m 
walk test (10MW). Assessment of dynamometric grip 
and pinch strength were evaluated with the Myogrio and 
Myopinch, as previously described [22]. All tests were 
conducted by trained and certified physiotherapists from 
the neuromuscular centre.
Timed tests
The subjects performed the 6MWT according to the 
modified ATS guidelines [23]. For RFF, trained examiners 
recorded using a stopwatch the time taken by the patient 
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to complete the task of rising from supine to standing as 
fast as possible. For the 4SC, the subject had to climb a 
four-step flight of stairs as fast as possible. For the 10MW, 
the subject had to walk or run for ten meters in a straight 
line. We recorded the time taken to complete the task as 
fast as possible. In order to ascertain that the patient’s 
best performance is captured, each of these tests were 
performed three times with a 1-min rest between each 
trial and we kept the test performed at the highest speed.
Movement monitoring
The ActiMyo® device (Sysnav, Vernon, France) was worn 
for 1 month at baseline and at 12 months. The two sen-
sors, each containing a magneto-inertial sensor that 
records the linear acceleration, the angular velocity and 
the magnetic field of the movement in all directions, 
were fixed to the dominant wrist and ankle. According 
to the EMA, for the purposes of qualification, a record-
ing is considered as valid if it includes at least 50  h of 
recording; optimally it should include 180 h of recording 
[16]. We studied three different variables: stride length, 
stride velocity, and the number of meters walked per 
hour. Stride length and stride velocity were studied as the 
medians (SL50C and SV50C) or the 95th centiles (SL95C 
or SV95C).
Upper limb measurement is still a work in progress and 
will be presented elsewhere.
Statistical analysis
For analysis, data were excluded from subjects who 
recorded less than 50  h; 9 subjects at baseline and 18 
subjects at follow-up, respectively. Analysis was first 
performed on the whole sample and then we analysed 
children (5 to 17  years) and adults (18  years and older) 
separately. Then within these groups, we analysed male 
and female subgroups. We used a series of Mann–Whit-
ney U tests to compare subgroups. We then performed 
correlation analyses using Spearman’s rank correla-
tion coefficient based on accelerometer measures, time 
test performances, age, and height. Finally, we use the 
Wilcoxon test to assess the evolution of each measure 
after 12  months. For compliance analysis, we used the 
50-h and 180-h thresholds as these two thresholds were 
defined in the EMA qualification document as accept-
able and optimal, respectively (16). All analyses were per-
formed using IBM’s SPSS Statistics software. The limit of 
statistical significance was set to 0.05.
Results
Population
We included 91 healthy individuals (41 males (45.1%) 
and 50 females (54.9%) aged between 6 and 85  years, 
with a mean age of 16 years 2 months. Seven participants 
withdrew between the baseline and the follow-up visit for 
personal reasons. A flow chart of subject participation is 
shown in Fig. 1. The demographic and clinical character-
istics of participants whose baseline data were analysed, 
as well as ActiMyo® variables, are provided in Table 1.
Statistical analysis was performed on data from the 82 
participants who achieved more than 50 h of recording at 
baseline. For further analysis, healthy subjects were dis-
tributed into two age subgroups: those 5 to 17  years of 
age and those aged 18 years and older. The first subgroup 
was composed of 65 participants, 34 of whom were 
females (52.3%). The second group was composed of 17 
participants, of whom 12 were females (70.6%).
The two age groups differed from each other in most 
measures including height, 6MWD, 4SC, RFF, and stride 
characteristics (SV50C, SV95C, SL50C and SL95C). 
Younger subjects were shorter (p < 0.001) but had a 
higher 6MWD (p = 0.011) than adults. The younger 
group also performed better at 4SC (p = 0.001) and RFF 
(p < 0.001). The groups did not differ significantly in 
10MW performance (p = 0.079). Regarding measure-
ments obtained with the magneto-inertial device, the 
groups did not differ significantly in the distance walked 
per hour (p = 0.215). SV50C tended to be higher in the 
adult group (p = 0.047), whereas SV95C was higher in 
children (p = 0.001). We found a similar pattern in stride 
length measures: the median (SL50C) was higher in 
adults (p = 0.001) but the 95th centile (SL95C) was higher 
in children (p = 0.001). The ratio between the SV95C and 
the SV50C was three times higher in younger subjects 
than in adults, and the ratio between SL95C and SL50C 
was twice higher in younger subjects, which seems to 
indicate a more stereotyped walking patterns in adults.
Compliance in wearing the device
Among the 91 healthy controls who wore the wearable 
device for one month, 90% recorded more than 50 h, and 
77% recorded more than 180  h at baseline. During the 
second period, 86% recorded more than 50  h, and 73% 
recorded more than 180  h. The main reason reported 
by subjects who recorded less than 50  h was ‘technical 
issues’. There was no age or gender effect evident on the 
recording duration (data not shown).
Correlations between timed tests, stride parameters 
and walking activity
Table  2 presents correlation coefficients between stride 
parameters obtained using the wearable device and 
clinical measures at baseline in both subgroups. We 
also present data from the 82 subjects who achieved 
more than 50  h of recording at baseline. 6MWD was 
significantly correlated with SV50C, SV95C, and SL95C 
in the younger group. In the adult group, 6MWD was 
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only correlated with ‘maximum performance’ meas-
ures SV95C and SL95C. In the younger population, the 
impact of age and height was more obvious than in the 
adult population (Table  2). Among the group aged 5 to 
17 years, height was highly correlated with age, 6MWD, 
10MW, SV50C, SL50C, and weakly correlated with 
SV95C and SL95C. In adults, height was only correlated 
with stride length measures SL50C and SL95C. We found 
no correlation between recording duration and stride 
length, stride velocity, or walking activity (distance/h, 
Fig. 1 Flow-chart displaying the compliance and inclusion of subjects. Withdrawals resulted from loss of follow up (5 subjects) and withdrawal by 
the subject (2 subjects)
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p = 0.323; SV50C, p = 0.466; SV95C, p = 0.664; SL50C, 
p = 0.723 and SL95C, p = 0.798).
Gender effect
In the adult population, males showed statistically signifi-
cantly higher SL50C (p = 0.009) and SL95C (p = 0.001), 
probably because they are on average taller than women 
in the cohort (p = 0.048). There was no other difference 
between males and females in the adult group. In con-
trast, in the younger population, male subjects were taller 
than female subjects, but we did not detect significant 
differences in any qualitative real-life walking parameter 
between the two subgroups.
Longitudinal data
Changes after 12  months are presented in Table  3 and 
evolution of the measures obtained with the magneto-
inertial device in children are displayed in Fig.  2. We 
present data on the 73 subjects who achieved more than 
50 h of recording both at baseline and on follow-up vis-
its. Given the effects of growth, we investigated two sub-
groups separately. In the younger group, we observed a 
significant increase in functional measures (6MWD, 4SC, 
10MW) after one year. Of the measures obtained with 
the magneto-inertial device, only SL50C increased after 
one year. We did not observe a significant change after 
a year in adults in stride length, stride velocity, distance 
walked, 6MWD, or RFF with the exception of a slight 
improvement in the 10MW performance.
Table 1 Demographic and clinical characteristics of participants who recorded more than 50 h
Data are expressed in mean (SD) [Min–Max]. BMI body mass index, 6MWT 6-min walk distance, 4SC 4-stair climb; RFF rise from floor; 10MW 10-m walk test; SV50C 50th 




Sample size 82 17 65 31
Age (years) 16.9 (16.0) 43 (18.9) 10.1 (2.8) 10.6 (2.9)
[6.0–84.3] [18.0–84.3] [6.0–17.6] [6.1–17.6]
Sex: number of female (%) 46 (56.0%) 12 (70,6%) 34 (52.3%) 0 (0%)
Height (cm) 144.0 (18.3) 167.5 (10.6) 137.8 (14.6) 142.5 (15.1)
[114.0–195.0] [153.2–195.0] [114.0–173.3] [118.0–174.3]
BMI (kg/m2) 18.8 (4.5) 25.7 (3.6) 17.0 (2.5) 17.2 (2.4)
[13.2–32.8] [20.1–32.8] [13.2–26.1] [13.9–23.7]
6MWT (m) 594.7 (71.2) 551.5 (82.0) 606.0 (64.1) 618.2 (61.6)
[436.0–761.0] [436.0–716.0] [464.0–761.0] [496.0–761.0]
4SC (s) 1.4 (0.3) 1.6 (0.4) 1.3 (0.3) 1.3 (0.3)
[0.9–2.3] [1.1–2.3] [0.9–2.3] [1–2.3]
RFF (s) 1.8 (0.6) 2.7 (0.9) 1.6 (0.2) 1.57 (0.3)
[1.0–4.9] [1.2–4.9] [1.0–2.2] [1.0–2.2]
10WT (m) 4.8 (0.8) 5.1 (0.8) 4.7 (0.7) 4.5 (3.5)
[3.1–7.3] [4.1–7.3] [3.1–7.2] [3.5–5.7]
Distance/hour (m/h) 265.2 (87.2) 246.4 (89.5) 270.2 (86.5) 294.8 (88.9)
[39.9–484.4] [119.6–433.0] [39.9–484.4] [39.9–484.4]
SV50C (m/s) 1.0 (0.1) 1.1 (0.1) 1.0 (0.1) 1.0 (0.1)
[0.7–1.3] [0.7–1.3] [0.9–1.3] [0.9–1.3]
SV95C (m/s) 2.4 (0.6) 1.6 (0.3) 2.6 (0.4) 2.6 (0.4)
[1.1–3.6] [1.1–2.3] [1.6–3.6] [1.7–3.2]
SL50C (m) 1.1 (0.1) 1.2 (0.1) 1.0 (0.1) 1.1 (0.1)
[0.8–1.5] [0.8–1.5] [0.8–1.4] [0.8–1.4]
SL95C (m) 1.7 (0.2) 1.5 (0.2) 1.7 (0.2) 1.7 (0.2)
[1.1–2.3] [1.1–1.8] [1.4–2.3] [1.4–2.1]
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Discussion
As a result of this study, we provide normative data for 
spontaneous stride velocity, stride length and walking 
distance per hour obtained passively with a wearable 
device during a one-month recording period in a non-
controlled setting and the one-year evolution thereafter. 
Most previous studies using wearable devices provide us 
with quantitative parameters [24]. Qualitative gait analy-
sis as stride length and velocity were mostly obtained 
based on evaluations inside clinical facilities [25, 26]. 
Recently, several efforts were made to collect, in a home-
based setting, qualitative data from subjects with various 
diseases and control populations [18, 19, 22, 27]. How-
ever, to the best of our knowledge, we found no other 
published data regarding normative longitudinal evalu-
ations of spontaneous stride velocity, stride length, and 
walking activity in an everyday setting.
As suggested in previous findings [28], acquiring nor-
mative data was feasible. The overall compliance with 
device use was good. More than 90% of subjects wore 
the device more than the minimum requirement of 50 h, 
which indicates that wearing devices at the ankle and at 
the wrist for one month was acceptable for most partici-
pants. The main reason given for data collection below 
the 50-h threshold was ‘technical issues’, and compliance 
was not influenced by gender or age. In addition, the 
recording duration did not influence the variables that 
were studied.
Table 3 Evolution of measures after one year
Time effect was assessed by a rank Wilcoxon test for single sample (null 
hypothesis: median = 0). Significance level p ≤ 0.01**, p ≤ 0.05*. 6MWT: 6-min 
walk distance, 4SC: 4-stair climb; RFF: rise from floor; 10MW: 10-m walk test; 
SV50C: 50th centile stride velocity; SV95C: 95th centile stride velocity; SL50C: 
50th centile stride length; SL95C: 95th centile stride length
Subgroup 5–17 years old Over 18 years old
Characteristics Mean (SD) Sig Mean (SD) Sig
Δ6MWD (m) 33.6 (50.302) p = 0.000** 14.87 
(46.649)
p = 0.191
Δ4SC (s)  − 0.11 (0.288) p = 0.004**  − 0.02 
(0.463)
p = 0.875
ΔRFF (s)  − 0.07 (0.336) p = 0.293  − 0.24 
(0.736)
p = 0.239
Δ10MW (s)  − 0.76 (0.77) p = 0.000**  − 0.52 
(0.632)
p = 0.011*
ΔDistance (m/h)  − 17.23 
(76.17)
p = 0.059 9.38 (67.15) p = 0.609
ΔSV50C (m/s) 0.01 (0.078) p = 0.359 0.01 (0.154) p = 0.691
ΔSV95C (m/s)  − 0.12 (0.447) p = 0.112 0.12 (0.389) p = 0.955
ΔSL50C (m) 0.05 (0.06) p = 0.000** 0.01 (0.095) p = 0.427
ΔSL95C (m) 0,02 (0.184) p = 0.241 0,04 (0.133) p = 0.691
A B
C D
Fig. 2 One year evolution of SV50C (A), SV95C (B), SL50C (C) and SL95C (D) in subjects aged 5 to 17 years. SV50C 50th centile stride velocity; SV95C 
95th centile stride velocity; SL50C 50th centile stride length; SL95C 95th centile stride length
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As expected, results of timed tests were growth 
dependent [22]. We also observed the influence of 
height (in adults) and height and growth (in children) 
on stride length. These results support previous find-
ings [29, 30]. Height did not influence SV95C, for 
which only a very weak inverse correlation was found 
with height in the adult subgroup only. In children, all 
correlations between age, height and stride length or 
speed were much weaker with maximum performance 
as measured by the 95th centile than with median val-
ues. Independence of growth is an advantage in clinical 
trials that are conducted in children over 1 or 2 years, 
especially in DMD where growth is altered by steroid 
use.
In comparison to ambulant DMD patients of the 
same age, healthy children present a 67.3% higher 
SV95C [17]. The difference for other variables was 
not as extreme, and there is some overlap between 
DMD and control participants (SL50C 31.39%, SL95C 
52.41%, SV50C 25.72%, distance walked/hour 63.13%) 
[16]. SV95C was stable after one year in controls but 
significantly and constantly decreases in subjects with 
DMD. In DMD patients, there is a significant correla-
tion between SV95C and all timed tests [17]. We did 
not find such correlations in controls, which is probably 
related to the fact that weakness constitutes a common 
limiting factor on 6MWD and SV95C in patients with 
DMD, strengthening the correlation in this group.
Gathering normative data is crucial in the validation 
process of an outcome measure, as it allows identifica-
tion of potentially confounding variables such as age, 
height, or gender. For a specific outcome, the norma-
tive data can either show a strong ceiling effect, as is 
the case for most of normative scales such as CHOP 
Intend, NSAA, and Motor Function Measure [31–34], 
or increases with age, as is the case for strength [21, 35] 
and the 6MWD [20].
The limitations of this study reside in the small num-
ber of controls per subgroup (age and gender), principally 
related to the limited availability of recording devices. 
Given the number of subjects, we did not study the sea-
sonal influence on the parameters. It is likely that a sea-
sonal analysis would need to take weather conditions 
into account, as they are more likely to influence walking 
behaviour than does the time of year, and would require 
continuous recording over one year, which could be bur-
densome in controls. Another limitation is that the BMI 
evolution of participants tends toward a more gradual 
increase than those of age-matched DMD, mainly after 
8  years of age [36]. However, this is not a major issue 
since there is no correlation between BMI and SV95C in 
both the adult and children subgroups. During the study, 
participants wore devices on both wrist and ankle. The 
analysis of upper limb movement in control patients is 
complex, since there is an interference with movement 
produced during the ambulation. The results will there-
fore be presented elsewhere, with comparison to the 
upper limb measures in ambulant and non-ambulant 
DMD patients.
Conclusion
This study provides evidence that normative data 
regarding stride length and velocity in a home-based 
environment with wearable sensors is feasible. These 
normative data will allow us to express a patient’s data 
as a percentage of predicted value for age or height and 
to identify those variables that have important con-
founding factors. There is still a large amount of work 
to be done to enable analysis of ambulation and upper 
limb function in various diseases using medical device 
for real-life mobility measurement. Future research 
should focus on exploring new fields of neurological 
disease and the creation of algorithms to study upper 
limb function, falls, or ataxia.
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